Evidence map›Paper›PMID 26826241›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1.

Celeste C Goh, Krystal M Roggerson, Hai-Chon Lee, Lucy Golden-Mason, Hugo R Rosen, Young S Hahn

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 105 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. NK-cell receptor modulation in viral infections.Clinical and experimental immunology · 2024
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Celeste C GohBeirne Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA 22908; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908;ORCID http://orcid.org/0000-0002-0070-3924
Krystal M RoggersonBeirne Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA 22908; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908;
Hai-Chon LeeBeirne Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA 22908; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908; Wide River Institute of Immunology, Seoul National University, Gangwon 25159, Korea; and.
Lucy Golden-MasonDepartment of Gastroenterology, University of Colorado Health Sciences Center, Aurora, CO 80045.ORCID http://orcid.org/0000-0003-3347-4192
Hugo R RosenDepartment of Gastroenterology, University of Colorado Health Sciences Center, Aurora, CO 80045.ORCID http://orcid.org/0000-0002-1110-6914
Young S HahnBeirne Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA 22908; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908; ysh5e@virginia.edu.ORCID http://orcid.org/0000-0002-2698-9844
Carter Center · USUniversity of Colorado Health · US

Funding

INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Suppression of HCV-specific CD4+ T Cells by Core ProteinU19AI066328 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HAHN, YOUNG S. · 2005 to 2014
$6.8M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
Role of HCV in aberrant APC activation/functionR01AI098126 · NIAID · UNIVERSITY OF VIRGINIA · PI HAHN, YOUNG S. · 2012 to 2016
$1.9M
Hampton University Biomedical Research Training Initiative (HUBIRTI)T34GM105550 · NIGMS · HAMPTON UNIVERSITY · PI PENN-MARSHALL, MICHELLE PAULETTE · 2014 to 2019
$1.6M
Alteration of innate immunity by HCV coreR01AI057591 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HAHN, YOUNG S. · 2005 to 2009
$1.5M
NIAID NIH HHS AI057591NIAID NIH HHS R01 AI057591NIAID NIH HHS R01 AI098126NIAID NIH HHS T32 AI007496NIAID NIH HHS T32 AI07496NIAID NIH HHS U19 AI066328NIGMS NIH HHS 1T34GM105550NIGMS NIH HHS T32 GM008715NIGMS NIH HHS T32 GM08715-14NIGMS NIH HHS T34 GM105550
6 · The paper itself

Abstract

The hepatitis C virus (HCV) infects ∼ 200 million people worldwide. The majority of infected individuals develop persistent infection, resulting in chronic inflammation and liver disease, including cirrhosis and hepatocellular carcinoma. The ability of HCV to establish persistent infection is partly due to its ability to evade the immune response through multiple mechanisms, including suppression of NK cells. NK cells control HCV replication during the early phase of infection and regulate the progression to chronic disease. In particular, IFN-γ produced by NK cells limits viral replication in hepatocytes and is important for the initiation of adaptive immune responses. However, NK cell function is significantly impaired in chronic HCV patients. The cellular and molecular mechanisms responsible for impaired NK cell function in HCV infection are not well defined. In this study, we analyzed the interaction of human NK cells with CD33(+) PBMCs that were exposed to HCV. We found that NK cells cocultured with HCV-conditioned CD33(+) PBMCs produced lower amounts of IFN-γ, with no effect on granzyme B production or cell viability. Importantly, this suppression of NK cell-derived IFN-γ production was mediated by CD33(+)CD11b(lo)HLA-DR(lo) myeloid-derived suppressor cells (MDSCs) via an arginase-1-dependent inhibition of mammalian target of rapamycin activation. Suppression of IFN-γ production was reversed by l-arginine supplementation, consistent with increased MDSC arginase-1 activity. These novel results identify the induction of MDSCs in HCV infection as a potent immune evasion strategy that suppresses antiviral NK cell responses, further indicating that blockade of MDSCs may be a potential therapeutic approach to ameliorate chronic viral infections in the liver.

Indexed as

ArginaseArginineCell LineCells, CulturedHepacivirusHepatitis CHumansInterferon-gammaKiller Cells, NaturalLeukocytes, MononuclearMyeloid CellsRNA Processing, Post-TranscriptionalSialic Acid Binding Ig-like Lectin 3Signal TransductionTOR Serine-Threonine KinasesArginaseArginineInterferon-gammaSialic Acid Binding Ig-like Lectin 3TOR Serine-Threonine Kinases

Identifiers

PMID26826241
PMCPMC4761460
OpenAlexW2413853065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.